Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

80.14 -0.98 (-1.20%)
Delayed Quote Updated: 11:13 AM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
22 23 Next >
News headline image
How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4) ↗
Mid-cap stocks surged in the past week, including CORT, COOP, and CRWV. GOOG may rent AI servers from CRWV. PRGS and LOAR reported strong results. 
Via Benzinga
Topics Artificial Intelligence Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast ↗
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer. 
Via Benzinga
News headline image
Why Is Corcept (CORT) Stock Soaring Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving... 
Via StockStory
Topics Artificial Intelligence
News headline image
Monday's session: top gainers and losers ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet ↗
 
Via Benzinga
Topics Stocks
News headline image
Mr. Cooper Group, Southern States Bancshares, Corcept Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Monday's pre-market session: top gainers and losers ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
3 Reasons to Sell CORT and 1 Stock to Buy Instead
Corcept currently trades at $58.76 and has been a dream stock for shareholders. It’s returned 434% since March 2020, blowing past the S&P 500’s 117% gain. The company has also beaten the index over the... 
Via StockStory
Topics Stocks
News headline image
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued. ↗
Uncover the potential of CORCEPT THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive... 
Via Chartmill
News headline image
3 Growth Stocks in Hot Water
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
News headline image
1 Small-Cap Stock on Our Buy List and 2 to Avoid
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Why Corcept (CORT) Shares Are Sliding Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.3% in the pre-market session after the company reported weak fourth quarter results: its revenue missed significantly, and its EPS... 
Via StockStory
News headline image
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 34.3% year on year to $181.9 million. On the other hand, the company’s... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics
Via Business Wire
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
CORCEPT THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:CORT is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
News headline image
Corcept (CORT) Q4 Earnings Report Preview: What To Look For
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
News headline image
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.